Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice

Nature Medicine

Volumn 23, Issue 4, 2017, Pages 429-438

  Beckerman, Pazit ^a   Bi Karchin, Jing ^a   Park, Ae Seo Deok ^a   Qiu, Chengxiang ^a   Dummer, Patrick D ^b   Soomro, Irfana ^c   Boustany Kari, Carine M ^d   Pullen, Steven S ^d   Miner, Jeffrey H ^e   Hu, Chien An A ^f   Rohacs, Tibor ^g   Inoue, Kazunori ^h   Ishibe, Shuta ^h   Saleem, Moin A ⁱ   Palmer, Matthew B ^j   Cuervo, Ana Maria ^k   Kopp, Jeffrey B ^b   Susztak, Katalin ^a,j  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c NEW YORK UNIVERSITY   (United States)

^d BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^g RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^h YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF BRISTOL   (United Kingdom)

^j UNIVERSITY OF PENNSYLVANIA   (United States)

^k ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN L1; UNCLASSIFIED DRUG; APOL1 PROTEIN, HUMAN; HIGH DENSITY LIPOPROTEIN;

AFRICAN AMERICAN; ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DISEASE COURSE; GENE EXPRESSION; GENETIC RISK; GENETIC VARIABILITY; GLOMERULOPATHY; KIDNEY DISEASE; MOUSE; NONHUMAN; PHENOTYPE; PODOCYTE; PRIORITY JOURNAL; ALBUMINURIA; ANIMAL; AUTOPHAGY; CHRONIC KIDNEY FAILURE; ELECTRON MICROSCOPY; ENDOCYTOSIS; ENDOSOME; FLUORESCENT ANTIBODY TECHNIQUE; FOCAL GLOMERULOSCLEROSIS; GENETIC PREDISPOSITION; GENETIC VARIATION; GENETICS; GLOMERULUS; HEK293 CELL LINE; HELA CELL LINE; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; PATHOLOGY; TRANSGENIC MOUSE; TUNEL ASSAY; ULTRASTRUCTURE; UREMIA; WESTERN BLOTTING;

ALBUMINURIA; ALLELES; ANIMALS; APOLIPOPROTEINS; AUTOPHAGY; AZOTEMIA; BLOTTING, WESTERN; ENDOCYTOSIS; ENDOSOMES; FLUORESCENT ANTIBODY TECHNIQUE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HEK293 CELLS; HELA CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; KIDNEY GLOMERULUS; LIPOPROTEINS, HDL; MICE; MICE, TRANSGENIC; MICROSCOPY, ELECTRON; PODOCYTES; RENAL INSUFFICIENCY, CHRONIC;

EID: 85013148525     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.4287     Document Type: Article

References (48)

1. USRDS. US Renal. Data Syst. (2015).
2. Lipworth, L. et al. Incidence and predictors of end stage renal disease among low-income blacks and whites. PLoS One 7, e48407 (2012).
3. Tzur, S. et al. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum. Genet. 128, 345-350 (2010).
4. Genovese, G. et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 329, 841-845 (2010).
5. Freedman, B.I. et al. Differential effects of MYH9 and APOL1 risk variants on FRMD3 Association with Diabetic ESRD in African Americans. PLoS Genet. 7, e1002150 (2011).
6. Foster, M.C. et al. APOL1 variants associate with increased risk of CKD among African Americans. J. Am. Soc. Nephrol. 24, 1484-1491 (2013).
7. Friedman, D.J. & Pollak, M.R. Genetics of kidney failure and the evolving story of APOL1. J. Clin. Invest. 121, 3367-3374 (2011).
8. Thomson, R. et al. Evolution of the primate trypanolytic factor APOL1. Proc. Natl. Acad. Sci. USA 111, E2130-E2139 (2014).
9. Lecordier, L. et al. Adaptation of Trypanosoma rhodesiense to hypohaptoglobinaemic serum requires transcription of the APOL1 resistance gene in a RNA polymerase I locus. Mol. Microbiol. 97, 397-407 (2015).
10. Bruggeman, L.A. et al. APOL1-G0 or APOL1-G2 transgenic models develop preeclampsia but not kidney disease. J. Am. Soc. Nephrol. 27, 3600-3610 (2016).
11. Madhavan, S.M. et al. APOL1 localization in normal kidney and nondiabetic kidney disease. J. Am. Soc. Nephrol. 22, 2119-2128 (2011).
12. Yu, H. et al. A role for genetic susceptibility in sporadic focal segmental glomerulosclerosis. J. Clin. Invest. 126, 1067-1078 (2016).
13. Larsen, C.P. et al. Histopathologic findings associated with APOL1 risk variants in chronic kidney disease. Mod. Pathol. 28, 95-102 (2015).
14. Kopp, J.B. et al. Clinical features and histology of apolipoprotein L1-associated nephropathy in the FSGS clinical trial. J. Am. Soc. Nephrol. 26, 1443-1448 (2015).
15. Ng, D.K. et al. APOL1-associated glomerular disease among African-American children: a collaboration of the Chronic Kidney Disease in Children (CKiD) and Nephrotic Syndrome Study Network (NEPTUNE) cohorts. Nephrol. Dial. Transplant. http://dx.doi.org/10.1093/ndt/gfw061 (2016).
16. Jotwani, V. et al. APOL1 genotype and glomerular and tubular kidney injury in women with HIV. Am. J. Kidney Dis. 65, 889-898 (2015).
17. Parsa, A. et al. APOL1 risk variants, race, and progression of chronic kidney disease. N. Engl. J. Med. 369, 2183-2196 (2013).
18. Tin, A. et al. Patterns of kidney function decline associated with APOL1 genotypes: results from AASK. Clin. J. Am. Soc. Nephrol. 11, 1353-1359 (2016).
19. Ledo, N. et al. Functional genomic annotation of genetic risk loci highlights inflammation and epithelial biology networks in CKD. J. Am. Soc. Nephrol. 26, 692-714 (2015).
20. Sampson, M.G. et al. Integrative genomics identifies novel associations with APOL1 risk genotypes in black NEPTUNE subjects. J. Am. Soc. Nephrol. 27, 814-823 (2016).
21. Zhaorigetu, S., Wan, G., Kaini, R., Jiang, Z. & Hu, C.A. ApoL1, a BH3-only lipid-binding protein, induces autophagic cell death. Autophagy 4, 1079-1082 (2008).
22. Furuta, N. & Amano, A. SNARE mediates autophagosome-lysosome fusion. Journal of Oral Biosciences 54, 83-85 (2012).
23. Müller-Deile, J. & Schiffer, M. Podocyte directed therapy of nephrotic syndrome-can we bring the inside out? Pediatr. Nephrol. 31, 393-405 (2016).
24. Tao, J., Polumbo, C., Reidy, K., Sweetwyne, M. & Susztak, K. A multicolor podocyte reporter highlights heterogeneous podocyte changes in focal segmental glomerulosclerosis. Kidney Int. 85, 972-980 (2014).
25. Byrne, B.G., Dubuisson, J.F., Joshi, A.D., Persson, J.J. & Swanson, M.S. Inflammasome components coordinate autophagy and pyroptosis as macrophage responses to infection. MBio 4, e00620-e12 (2013).
26. Shahzad, K. et al. Caspase-1, but not caspase-3, promotes diabetic nephropathy. J. Am. Soc. Nephrol. 27, 2270-2275 (2016).
27. Inoki, K. mTOR signaling in autophagy regulation in the kidney. Semin. Nephrol. 34, 2-8 (2014).
28. Nichols, B. et al. Innate immunity pathways regulate the nephropathy gene Apolipoprotein L1. Kidney Int. 87, 332-342 (2015).
29. Kasembeli, A.N. et al. APOL1 risk variants are strongly associated with HIV-associated nephropathy in Black South Africans. J. Am. Soc. Nephrol. 26, 2882-2890 (2015).
30. Thomson, R. & Finkelstein, A. Human trypanolytic factor APOL1 forms pH-gated cation-selective channels in planar lipid bilayers: relevance to trypanosome lysis. Proc. Natl. Acad. Sci. USA 112, 2894-2899 (2015).
31. Wan, G. et al. Apolipoprotein L1, a novel Bcl-2 homology domain 3-only lipid-binding protein, induces autophagic cell death. J. Biol. Chem. 283, 21540-21549 (2008).
32. Cheng, D. et al. Biogenesis and cytotoxicity of APOL1 renal risk variant proteins in hepatocytes and hepatoma cells. J. Lipid Res. 56, 1583-1593 (2015).
33. Galindo-Moreno, J. et al. Apolipoprotein L2 contains a BH3-like domain but it does not behave as a BH3-only protein. Cell Death Dis. 5, e1275 (2014).
34. Heneghan, J.F. et al. BH3 domain-independent apolipoprotein L1 toxicity rescued by BCL2 prosurvival proteins. Am. J. Physiol. Cell Physiol. 309, C332-C347 (2015).
35. Hartleben, B. et al. Autophagy influences glomerular disease susceptibility and maintains podocyte homeostasis in aging mice. J. Clin. Invest. 120, 1084-1096 (2010).
36. Hartleben, B., Wanner, N. & Huber, T.B. Autophagy in glomerular health and disease. Semin. Nephrol. 34, 42-52 (2014).
37. Kawakami, T. et al. Deficient autophagy results in mitochondrial dysfunction and FSGS. J. Am. Soc. Nephrol. 26, 1040-1052 (2015).
38. Tagawa, A. et al. Impaired podocyte autophagy exacerbates proteinuria in diabetic nephropathy. Diabetes 65, 755-767 (2016).
39. Yamamoto-Nonaka, K. et al. Cathepsin D in podocytes is important in the pathogenesis of proteinuria and CKD. J. Am. Soc. Nephrol. 27, 2685-2700 (2016).
40. Gabay, C., Lamacchia, C. & Palmer, G. IL-1 pathways in inflammation and human diseases. Nat. Rev. Rheumatol. 6, 232-241 (2010).
41. Turner, C.M., Arulkumaran, N., Singer, M., Unwin, R.J. & Tam, F.W. Is the inflammasome a potential therapeutic target in renal disease? BMC Nephrol. 15, 21 (2014).
42. Li, P. et al. Mice deficient in IL-1 beta-converting enzyme are defective in production of mature IL-1 beta and resistant to endotoxic shock. Cell 80, 401-411 (1995).
43. Doitsh, G. et al. Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature 505, 509-514 (2014).
44. Haque, S. et al. HIV promotes NLRP3 inflammasome complex activation in murine HIV-associated nephropathy. Am. J. Pathol. 186, 347-358 (2016).
45. Lin, X., Suh, J.H., Go, G. & Miner, J.H. Feasibility of repairing glomerular basement membrane defects in Alport syndrome. J. Am. Soc. Nephrol. 25, 687-692 (2014).
46. Klionsky, D.J. et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy 12, 1-222 (2016).
47. Sakairi, T. et al. Conditionally immortalized human podocyte cell lines established from urine. Am. J. Physiol. Renal Physiol. 298, F557-F567 (2010).
48. Soda, K. et al. Role of dynamin, synaptojanin, and endophilin in podocyte foot processes. J. Clin. Invest. 122, 4401-4411 (2012).